Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.
Twist Bioscience Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$117.41|
|52 Week High||US$74.25|
|52 Week Low||US$214.07|
|1 Month Change||4.73%|
|3 Month Change||2.10%|
|1 Year Change||36.57%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||738.64%|
Recent News & Updates
Twist Stock: Manufacturing The Future
Twist Bioscience is a synthetic biology company that is able to produce DNA at significantly lower costs than competitors. There is uncertainty as to whether Twist’s technological advantage is sustainable or if a more productive technology will be developed. Next-Generation Sequencing revenue growth is strong and is likely to remain so as costs continue to decline and applications like liquid biopsy are commercialized. Revenue from drug discovery and data storage is uncertain but could provide significant upside. Twist's stock is relatively expensive but this reflects the size of their opportunity.
Is Twist Bioscience (NASDAQ:TWST) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|TWST||US Biotechs||US Market|
Return vs Industry: TWST exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: TWST exceeded the US Market which returned 30.3% over the past year.
Stable Share Price: TWST is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: TWST's weekly volatility (9%) has been stable over the past year.
About the Company
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Twist Bioscience Fundamentals Summary
|TWST fundamental statistics|
Is TWST overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TWST income statement (TTM)|
|Cost of Revenue||US$75.70m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.74|
|Net Profit Margin||-106.59%|
How did TWST perform over the long term?See historical performance and comparison
Is Twist Bioscience undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TWST's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TWST's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TWST is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TWST is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TWST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TWST is overvalued based on its PB Ratio (9.5x) compared to the US Biotechs industry average (2.9x).
How is Twist Bioscience forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TWST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TWST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TWST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TWST's revenue (22.3% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: TWST's revenue (22.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TWST is forecast to be unprofitable in 3 years.
How has Twist Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TWST is currently unprofitable.
Growing Profit Margin: TWST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TWST is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare TWST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TWST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: TWST has a negative Return on Equity (-22.14%), as it is currently unprofitable.
How is Twist Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: TWST's short term assets ($576.6M) exceed its short term liabilities ($54.8M).
Long Term Liabilities: TWST's short term assets ($576.6M) exceed its long term liabilities ($60.0M).
Debt to Equity History and Analysis
Debt Level: TWST's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TWST's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TWST has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TWST has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.1% each year
What is Twist Bioscience current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TWST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TWST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TWST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TWST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TWST's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Emily Leproust (48 yo)
Dr. Emily Marine Leproust, Ph D., serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at Sema4 Holdings Corp. (formerly known as Mount Si...
CEO Compensation Analysis
Compensation vs Market: Emily's total compensation ($USD7.44M) is about average for companies of similar size in the US market ($USD6.33M).
Compensation vs Earnings: Emily's compensation has been consistent with company performance over the past year.
Experienced Management: TWST's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: TWST's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TWST insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.
Twist Bioscience Corporation's employee growth, exchange listings and data sources
- Name: Twist Bioscience Corporation
- Ticker: TWST
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.787b
- Shares outstanding: 49.29m
- Website: https://www.twistbioscience.com
Number of Employees
- Twist Bioscience Corporation
- 681 Gateway Boulevard
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 22:26|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.